Company Nanoform Finland Oyj

Equities

NANOFH

FI4000330972

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Nanoform Finland Oyj

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Helsinki Other stock markets 11:15:46 2024-04-19 am EDT			5-day change	1st Jan Change
2.54 ^EUR	+3.04%		-0.20%	+60.25%

Apr. 11	Nanoform Finland to Deliver Nanomedicine Technology to Japan	MT
Apr. 11	Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan	CI

Nanoform Finland Oyj is a Finland-based company that operates in the global pharmaceutical industry. The Company is an early-stage growth Company that develops various nanoforming technologies for application in the field of nanomedicine. Nanoform Finland Oyj's business is to offer expert services in nanotechnology as well as drug particle engineering for global pharma and biotech industry. Nanoform Finland Oyj is the Parent Company of the Nanoform Group, and it has one subsidiary - Nanoform USA Inc. The Group production, research and development functions operate in Finland. The Group's strategy is to sell nanotechnological services widely to minimize the dependence from single customers or projects.

Number of employees: 165

EUR in Million	2022	Weight	2023	Weight	Delta
Nanotechnology and Drug Particle Engineering 100.0 %	3	100.0 %	3	100.0 %	-26.41%

EUR in Million	2022	Weight	2023	Weight	Delta
Europe 57.0 %	2	56.2 %	1	57.0 %	-25.37%
United States 43.0 %	2	43.8 %	1	43.0 %	-27.73%

Managers	Title	Age	Since
Edward Hæggström CEO	Chief Executive Officer	55	14-12-31
Albert Häggström DFI	Director of Finance/CFO	53	14-12-31
Henri von Haartman IRC	Investor Relations Contact	-	19-04-30
Antonio da Silva PRN	Corporate Officer/Principal	50	18-12-31
Peter Hänninen LAW	General Counsel	36	20-08-31
David Rowe PRN	Corporate Officer/Principal	57	18-12-31
Christian Jones PRN	Corporate Officer/Principal	44	17-12-31

Members of the board	Title	Age	Since
Miguel Laustsen de Oliveira Barreiros Calado CHM	Chairman	68	19-04-01
Mads Laustsen BRD	Director/Board Member	67	18-12-31
Albert Häggström DFI	Director of Finance/CFO	53	14-12-31
Jeanne A. Thoma BRD	Director/Board Member	65	21-09-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	78,445,164	52,636,291 ( 67.10 %)	0	67.10 %

Name	Equities	%	Valuation
Edward Hæggström 6.896 %	5,409,405	6.896 %	16 M €
Helsingin Yliopiston Rahastot 5.606 %	4,397,719	5.606 %	13 M €
MANDATUM OYJ 5.490 %	4,306,834	5.490 %	13 M €
Fjärde AP-fonden 4.736 %	3,715,050	4.736 %	11 M €
Keskinäinen Työeläkevakuutusyhtiö Varma 3.910 %	3,066,996	3.910 %	9 M €
Keel Capital AB 3.874 %	3,039,112	3.874 %	9 M €
ATP Arbejdsmarkedets Tillægspension 3.443 %	2,700,708	3.443 %	8 M €
Arbejdsmarkedets Tillægspension 3.443 %	2,700,708	3.443 %	8 M €
Kai Falck 3.442 %	2,700,000	3.442 %	8 M €
Jouko Yliruusi 3.423 %	2,685,182	3.423 %	8 M €

Nanoform Finland Oyj

Cultivator II Viikinkaari 4

00790, Helsinki

+358 2937 00150

http://www.nanoform.fi

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.54 EUR

Average target price

4.4 EUR

Spread / Average Target

+73.23%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
NANOFORM FINLAND OYJ	+60.25%	206M
IQVIA HOLDINGS INC.	-1.42%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.97%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.82%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.68B
MEDPACE HOLDINGS, INC.	+21.36%	11.6B
UNITED THERAPEUTICS CORPORATION	+8.20%	11.15B

Other Biotechnology & Medical Research